T-Cell Immunotherapy: Looking Forward
Abstract
The rapidly expanding field of T-cell immunotherapy has experienced clinical successes along with some serious toxicities. "T Cell Immunotherapy: Optimizing Trial Design," a workshop sponsored by the National Institutes of Health's (NIH's) Office of Biotechnology Activities (OBA), brought together researchers to discuss the scientific advances and share new data on key trial design issues, including the selection of new targets, optimizing the T-cell population, preconditioning regimens, strategies to promote persistence of cells, and analysis and management of acute reactions to T-cell infusions with the goal of identifying best practices and a research agenda that will facilitate further development and maximize the safety of this promising approach.
Additional Information
© 2014 The American Society of Gene & Cell Therapy. The authors thank all the participants for their contributions. The views expressed in this paper are those of the individual authors and do not represent the views of the NIH or the FDA. C.J. has sponsored research support from Novartis through a grant that supports research in the field of CARs for oncology. He also has intellectual property in the area of adoptive cell therapy that is owned by the University of Pennsylvania and the US government. This has been licensed to Novartis. Both the university and C.J. may receive royalties; this arrangement is managed in accordance with the University of Pennsylvania policies and oversight. L.C. founded and owns InCellerate, Inc. He has patents with Sangamo BioSciences with artificial nucleases. He consults with Targazyme, Inc. (formerly American Stem cells, Inc.), GE Healthcare, Ferring Pharmaceuticals, Inc., and Bristol-Myers Squibb. He receives honoraria from Miltenyi Biotec. D.P. holds patents for CARs that are licensed to companies or institutions that may gain or lose value from publication of the article. R.J.B., M.S., and P.G. are scientific founders and stockholders in Juno Therapeutics, Inc., as well as consultants for the company. H.H. has a licensing agreement with Cell Medica, and her institution has a collaborative research agreement with Celgene Corporation. C.M. has a patent pending on CD22-CAR and has received research funding from Neomune. M.J. is a consultant, inventor of licensed patents, recipient of SRA funding, and equity holder in Juno Therapeutics, Inc. S.G.'s institution has research collaborations with Celgene Corporation and bluebird bio. He has been funded by the DANA Foundation, the James S. McDonnell Foundation, and Cancer Prevention Research Institute Texas grant RP101335. H.H. and S.F. are supported by grants P01CA094237, P50CA126752, and U54HL08100 from the NIH and a SCOR award from the Leukemia and Lymphoma Society.Additional details
- PMCID
- PMC4435492
- Eprint ID
- 50250
- DOI
- 10.1038/mt.2014.148
- Resolver ID
- CaltechAUTHORS:20141008-074936325
- Novartis
- Neomune
- DANA Foundation
- James S. McDonnell Foundation
- RP101335
- Cancer Prevention Research Institute Texas
- P01CA094237
- NIH
- P50CA126752
- NIH
- U54HL08100
- NIH
- Leukemia and Lymphoma Society
- Created
-
2014-10-09Created from EPrint's datestamp field
- Updated
-
2021-11-10Created from EPrint's last_modified field